Hyaluronan accumulates with high-fat feeding and contributes to insulin resistance

Diabetes

Volumn 62, Issue 6, 2013, Pages 1888-1896

  Kang, Li ^a,b   Lantier, Louise ^a   Kennedy, Arion ^a   Bonner, Jeffrey S ^a   Mayes, Wesley H ^a   Bracy, Deanna P ^a   Bookbinder, Louis H ^c   Hasty, Alyssa H ^a   Thompson, Curtis B ^c   Wasserman, David H ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c Halozyme Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONIC ACID; PEGYLATED HUMAN RECOMBINANT PH20 HYALURONIDASE; RECOMBINANT HYALURONIDASE; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SIZE; CONTROLLED STUDY; DOSE RESPONSE; EXTRACELLULAR MATRIX; FAT MASS; GLUCOSE TRANSPORT; HEART OUTPUT; INSULIN RESISTANCE; LIPID DIET; MALE; MOUSE; MUSCLE BLOOD VESSEL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CELL ADHESION MOLECULES; DIET, HIGH-FAT; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; OBESITY;

EID: 84878243502     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-1502     Document Type: Article

References (48)

1. Huang G, Greenspan DS. ECM roles in the function of metabolic tissues. Trends Endocrinol Metab 2012;23:16-22
2. Coletta DK, Mandarino LJ. Mitochondrial dysfunction and insulin resistance from the outside in: extracellular matrix, the cytoskeleton, and mitochondria. Am J Physiol Endocrinol Metab 2011;301:E749-E755
3. Kang L, Ayala JE, Lee-Young RS, et al. Diet-induced muscle insulin resistance is associated with extracellular matrix remodeling and interaction with integrin alpha2beta1 in mice. Diabetes 2011;60:416-426
4. Pasarica M, Gowronska-Kozak B, Burk D, et al. Adipose tissue collagen VI in obesity. J Clin Endocrinol Metab 2009;94:5155-5162
5. Lewis A, Steadman R, Manley P, et al. Diabetic nephropathy, inflammation, hyaluronan and interstitial fibrosis. Histol Histopathol 2008;23:731-739 (Pubitemid 351552358)
6. Aumailley M, Gayraud B. Structure and biological activity of the extracellular matrix. J Mol Med (Berl) 1998;76:253-265 (Pubitemid 28098711)
7. Berria R, Wang L, Richardson DK, et al. Increased collagen content in insulin-resistant skeletal muscle. Am J Physiol Endocrinol Metab 2006;290:E560-E565 (Pubitemid 43671704)
8. Chajara A, Raoudi M, Delpech B, Leroy M, Basuyau JP, Levesque H. Increased hyaluronan and hyaluronidase production and hyaluronan degradation in injured aorta of insulin-resistant rats. Arterioscler Thromb Vasc Biol 2000;20:1480-1487 (Pubitemid 30353877)
9. Weiss L, Slavin S, Reich S, et al. Induction of resistance to diabetes in nonobese diabetic mice by targeting CD44 with a specific monoclonal antibody. Proc Natl Acad Sci USA 2000;97:285-290 (Pubitemid 30055823)
10. Melin J, Hellberg O, Funa K, Hällgren R, Larsson E, Fellström BC. Ischemia-induced renal expression of hyaluronan and CD44 in diabetic rats. Nephron, Exp Nephrol 2006;103:e86-e94 (Pubitemid 43952613)
11. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004;4:528-539 (Pubitemid 38868622)
12. Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev 2011;91:221-264
13. Bookbinder LH, Hofer A, Haller MF, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006;114:230-241 (Pubitemid 44291844)
14. Thompson CB, Shepard HM, O'Connor PM, et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther 2010;9:3052-3064
15. Jiang P, Li X, Thompson CB, et al. Effective targeting of the tumor microenvironment for cancer therapy. Anticancer Res 2012;32:1203-1212
16. Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013;62:112-120
17. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012;21:418-429
18. Dasu MR, Devaraj S, Park S, Jialal I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 2010;33:861-868
19. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 1988;37:1163-1167 (Pubitemid 19035045)
20. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH. Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 2006;55:390-397 (Pubitemid 43343268)
21. Berglund ED, Li CY, Poffenberger G, et al. Glucose metabolism in vivo in four commonly used inbred mouse strains. Diabetes 2008;57:1790-1799
22. Ayala JE, Bracy DP, Julien BM, Rottman JN, Fueger PT, Wasserman DH. Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes 2007;56:1025-1033 (Pubitemid 46525081)
23. Steele R, Wall JS, De Bodo RC, Altszuler N. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 1956;187:15-24
24. Kraegen EW, James DE, Jenkins AB, Chisholm DJ. Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. Am J Physiol 1985;248:E353-E362 (Pubitemid 15076599)
25. Lee-Young RS, Griffee SR, Lynes SE, et al. Skeletal muscle AMP-activated protein kinase is essential for the metabolic response to exercise in vivo. J Biol Chem 2009;284:23925-23934
26. Bonner JS, Lantier L, Hasenour CM, James FD, Bracy DP, Wasserman DH. Muscle-Specific vascular endothelial growth factor deletion induces muscle capillary rarefaction creating muscle insulin resistance. Diabetes. 21 September 2012 [Epub ahead of print]
27. Jørgensen SB, Viollet B, Andreelli F, et al. Knockout of the alpha2 but not alpha1 5′-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. J Biol Chem 2004;279:1070-1079 (Pubitemid 38082628)
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408 (Pubitemid 34164012)
29. Whatcott CJ, Han H, Posner RG, Hostetter G, Von Hoff DD. Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov 2011;1:291-296
30. Redman LM, Ravussin E. Caloric restriction in humans: impact on physiological, psychological, and behavioral outcomes. Antioxid Redox Signal 2011;14:275-287
31. Niskanen L, Uusitupa M, Sarlund H, Siitonen O, Paljärvi L, Laakso M. The effects of weight loss on insulin sensitivity, skeletal muscle composition and capillary density in obese non-diabetic subjects. Int J Obes Relat Metab Disord 1996;20:154-160 (Pubitemid 26050946)
32. Toledo FG, Menshikova EV, Ritov VB, et al. Effects of physical activity and weight loss on skeletal muscle mitochondria and relationship with glucose control in type 2 diabetes. Diabetes 2007;56:2142-2147 (Pubitemid 47195831)
33. Bergman RN, Bradley DC, Ader M. On insulin action in vivo: the single gateway hypothesis. Adv Exp Med Biol 1993;334:181-198 (Pubitemid 23303358)
34. Frederiksen L, Nielsen TL, Wraae K, et al. Subcutaneous rather than visceral adipose tissue is associated with adiponectin levels and insulin resistance in young men. J Clin Endocrinol Metab 2009;94:4010-4015
35. O'Connell J, Lynch L, Cawood TJ, et al. The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. PLoS ONE 2010;5:e9997
36. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-867 (Pubitemid 46024993)
37. Shoelson SE, Lee J, Gold fine AB. Inflammation and insulin resistance. J Clin Invest 2006;116:1793-1801 (Pubitemid 44033299)
38. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35 (Pubitemid 37328697)
39. Toole BP. Hyaluronan is not just a goo! J Clin Invest 2000;106:335-336 (Pubitemid 30655632)
40. Kodama K, Horikoshi M, Toda K, et al. Expression-based genome-wide association study links the receptor CD44 in adipose tissue with type 2 diabetes. Proc Natl Acad Sci USA 2012;109:7049-7054
41. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990;61:1303-1313
42. Su AI, Wiltshire T, Batalov S, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 2004;101:6062-6067 (Pubitemid 38520528)
43. Cao G, Savani RC, Fehrenbach M, et al. Involvement of endothelial CD44 during in vivo angiogenesis. Am J Pathol 2006;169:325-336
44. Päll T, Pink A, Kasak L, et al. Soluble CD44 interacts with intermediate filament protein vimentin on endothelial cell surface. PLoS ONE 2011;6:e29305
45. Turley EA, Austen L, Vandeligt K, Clary C. Hyaluronan and a cell-associated hyaluronan binding protein regulate the locomotion of ras-transformed cells. J Cell Biol 1991;112:1041-1047 (Pubitemid 21909648)
46. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010;375:2267-2277
47. Tritos NA, Mantzoros CS. Clinical review 97: syndromes of severe insulin resistance. J Clin Endocrinol Metab 1998;83:3025-3030 (Pubitemid 28500929)
48. Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 2004;47:1661-1667 (Pubitemid 40022398)